Glucosamine: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: April 9, 2026🚩 Report this page

Glucosamine

Other Antiinflammatory and Antirheumatic Agents, Non-Steroids

GB MHRA

Drug class: Other Antiinflammatory and Antirheumatic Agents, Non-Steroids
Availability: See label
Markets covered: 1
Products on record: 7

M01AXOther Antiinflammatory and Antirheumatic Agents, Non-Steroids

Overview

Glucosamine is an active pharmaceutical ingredient in the Other Antiinflammatory and Antirheumatic Agents, Non-Steroids group (M01AX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	7	April 9, 2026

GBUnited Kingdom· MHRA

7 products

Uses

GBOfficial regulatory label· revised January 9, 2026[1]

Relief of symptoms in mild to moderate osteoarthritis of the knee.

How to take

GBOfficial regulatory label

Drug interactions

Known interactions involving Glucosamine. Select one for details. This list is informational and not a complete interaction checker.

Anisindione Dicumarol Warfarin

Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.

Sources & citations

[1]MHRA (UK) · PL438700036 · revised January 9, 2026

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised January 9, 2026[1]

The most common adverse reactions associated with treatment with glucosamine are described below. The reported adverse reactions are usually mild and transitory. In the table below, all causality adverse events are listed by system organ class and frequency (very common ≥1/10; common ≥1/100 to <1/10; uncommon ≥1/1,000 to <1/100; rare ≥1/10,000 to <1/1,000; very rare <1/10,000; not known (cannot be estimated from the available data)).
MedDRA System Organ Class Common (>1/100 to <1/10) Uncommon (>1/1000 to <1/100) Not known (cannot be estimated from the available data) Nervous system disorders Headache Tiredness - Dizziness Respiratory, thoracic and mediastinal disorders - - Asthma / Asthma aggravated Gastrointestinal disorders Nausea Abdominal pain Indigestion Diarrhoea Constipation - Vomiting Skin and subcutaneous tissue disorders - Rash Itching Flushing Angioedema Urticaria Metabolism and nutrition disorders - - Diabetes mellitus inadequate control Hypercholesterolae mia General disorders and administration site conditions - - Oedema / Peripheral oedema Cases of hypercholesterolemia, asthma, aggravated and diabetes mellitus inadequate control have been reported, but causality has not been established.
Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised January 9, 2026[1]

Glucosamine should not be used in children and adolescents below the age of 18, due to lack of data on safety and efficacy. A doctor should be consulted to rule out the presence of joint diseases for which other treatments should be considered.
In patients with impaired glucose tolerance, monitoring of the blood glucose levels and, where relevant, insulin requirements is recommended before start of treatment and periodically during treatment. In patients with a known risk factor for cardiovascular disease, monitoring of the blood lipid levels recommended, since hypercholesterolemia has been observed in a few cases in patients treated with glucosamine.
A report on exacerbated asthma symptoms triggered after initiation of glucosamine therapy is available (symptoms resolved after withdrawal of glucosamine). Asthmatic patients starting on glucosamine should therefore be aware of potential worsening of asthmatic symptoms.
Glucosamine contains sorbitol. Patients with hereditary problems of fructose intolerance should not take this medicine. This medicinal product contains 320 mg sodium per tablet, equivalent to 16% of the WHO. Should be used with caution in patients with cardiac insufficiency.

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

GBUnited Kingdom· MHRA

Drug interactions

Drugs in the same class

Sources & citations